Correction
Psychopharmacol Bull. 2024 Apr 4;54(2):53-55.ABSTRACT[This corrects the article , PMID: 37601085.].PMID:38601829 | PMC:PMC11003260 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - April 11, 2024 Category: Psychiatry & Psychology Source Type: research
Clavulanic Acid Decreases Cocaine Cue Reactivity in Addiction-Related Brain Areas, a Randomized fMRI Pilot Study
CONCLUSION: CLAV reduced the response of the brain regions associated with motivation and emotional response during the DOWN condition compared to PBO, suggesting CLAV may strengthen voluntary efforts to avoid cocaine use. This pilot data supports the use of CLAV for CUD. (Trial registered in ClinicalTrials.gov NCT04411914).PMID:38601830 | PMC:PMC11003254 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - April 11, 2024 Category: Psychiatry & Psychology Authors: Linda S Callans Helene Philogene-Khalid Kanchana Jagannathan Ronan Cunningham Daohai Yu Xiaoning Lu M Ingre Walters Mary F Morrison Source Type: research
A Bell's Palsy Case Probably Related to Sertraline Use
Psychopharmacol Bull. 2024 Apr 4;54(2):51-52.NO ABSTRACTPMID:38601831 | PMC:PMC11003255 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - April 11, 2024 Category: Psychiatry & Psychology Authors: Mehmet Emin Ceylan Bar ış Önen Ünsalver Hatice Zeynep Ceylan Source Type: research
Zolpidem Stimulant Effect and Dependence: A Case Report on Intranasal Use
We present the first case of a patient who developed zolpidem dependence, which was associated with the prompt onset of euphoria exclusively following intranasal use. Mr. A was a 51-year-old polydrug abuser with antisocial personality disorder and a physical dependence on zolpidem. Over several years, he consumed 500 mg of the drug daily, usually divided into 30 mg doses, exclusively via the nasal route because unlike the oral administration of the same dose of the drug, intranasal administration induced euphoria. Euphoric effects manifested 3-5 minutes after taking the drug, and pronounced withdrawal symptoms (i.e., profu...
Source: Psychopharmacology Bulletin - April 11, 2024 Category: Psychiatry & Psychology Authors: Branimir Margeti ć Marina Alaber Source Type: research
Case Report on High Dose Lithium Treatment for Post-COVID Depression, Recurrent Fevers, and Skin Lesions
Psychopharmacol Bull. 2024 Apr 4;54(2):39-45.ABSTRACTThis is a case of a 35-year-old woman who presented with an 18-month history of post (long)-COVID depression and exhaustion along with recurrent fevers and treatment-resistant skin boils, all of which abated with lithium treatment at a serum level of 1.14 mmol/L, and all of which worsened when the lithium serum level was lowered to 0.8. This paper illustrates Lithium's effectiveness in the treatment of post (long)-COVID syndrome, though a higher serum concentration may be required.PMID:38601833 | PMC:PMC11003256 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - April 11, 2024 Category: Psychiatry & Psychology Authors: Lila Elizabeth Massoumi Alan Rosenbaum Source Type: research
Efficacy of Rivastigmine Augmentation on Positive and Negative Symptoms, General Psychopathology, and Quality of Life in Patients with Chronic Schizophrenia: A Randomized Controlled Trial
Psychopharmacol Bull. 2024 Apr 4;54(2):15-27.ABSTRACTThe study aimed to assess Rivastigmine augmentation on positive and negative symptoms (PNSs), general psychopathology, and quality of life in patients with chronic Schizophrenia. A double-blind, parallel-design, randomized, placebo-controlled trial of 60 schizophrenia patients was conducted. Intervention group received rivastigmine 3 mg/day + Treatment as Usual (TAU) and the control group: TAU + placebo. Negative and positive symptoms, general psychopathology; and quality of life were measured using Positive and Negative Symptom Scale (PANSS) and Manchester Short Assessm...
Source: Psychopharmacology Bulletin - April 11, 2024 Category: Psychiatry & Psychology Authors: Sepideh Herizchi Ali Reza Shafiee-Kandjani Mostafa Farahbakhsh Zahra Jahangiri Shahriyar Ghanbarzadeh Javid Hosein Azizi Source Type: research
Clozapine Prescripers-Dogmatic or Pragmatic?
Psychopharmacol Bull. 2024 Apr 4;54(2):46-50.ABSTRACTClozapine, amongst antipsychotics, has a unique composite mode of action that might translate into an expanded therapeutic potential on clinical grounds. Sorely, clozapine remains underutilized.PMID:38601835 | PMC:PMC11003257 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - April 11, 2024 Category: Psychiatry & Psychology Authors: Ahmed Naguy Hessa Alhazeem Source Type: research
A Unique Delusion with Depression in Early Stage of Neurocognitive Disorder Due to Vascular Disease: Considerations for Clinicians
Psychopharmacol Bull. 2024 Apr 4;54(2):28-33.ABSTRACTAs global aging becomes more prominent, neurocognitive disorders (NCD) incidence has increased. Patients with NCD usually have an impairment in one or more cognitive domains, such as attention, planning, inhibition, learning, memory, language, visual perception, and spatial or social skills. Studies indicate that 50-80% of these adults will develop neuropsychiatric symptoms (NPS), such as apathy, depression, anxiety, disinhibition, delusions, hallucinations, and aberrant motor behavior. The progression of NCD and subsequent NPS requires tremendous care from trained medic...
Source: Psychopharmacology Bulletin - April 11, 2024 Category: Psychiatry & Psychology Authors: Mounica Thootkur Binx Yezhe Lin Akhil S Pola Alexander Zhang Zhengshan Liu Michael Greenage Justin White Mamta Sapra Source Type: research
Correction
Psychopharmacol Bull. 2024 Apr 4;54(2):53-55.ABSTRACT[This corrects the article , PMID: 37601085.].PMID:38601829 | PMC:PMC11003260 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - April 11, 2024 Category: Psychiatry & Psychology Source Type: research
Clavulanic Acid Decreases Cocaine Cue Reactivity in Addiction-Related Brain Areas, a Randomized fMRI Pilot Study
CONCLUSION: CLAV reduced the response of the brain regions associated with motivation and emotional response during the DOWN condition compared to PBO, suggesting CLAV may strengthen voluntary efforts to avoid cocaine use. This pilot data supports the use of CLAV for CUD. (Trial registered in ClinicalTrials.gov NCT04411914).PMID:38601830 | PMC:PMC11003254 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - April 11, 2024 Category: Psychiatry & Psychology Authors: Linda S Callans Helene Philogene-Khalid Kanchana Jagannathan Ronan Cunningham Daohai Yu Xiaoning Lu M Ingre Walters Mary F Morrison Source Type: research
A Bell's Palsy Case Probably Related to Sertraline Use
Psychopharmacol Bull. 2024 Apr 4;54(2):51-52.NO ABSTRACTPMID:38601831 | PMC:PMC11003255 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - April 11, 2024 Category: Psychiatry & Psychology Authors: Mehmet Emin Ceylan Bar ış Önen Ünsalver Hatice Zeynep Ceylan Source Type: research
Zolpidem Stimulant Effect and Dependence: A Case Report on Intranasal Use
We present the first case of a patient who developed zolpidem dependence, which was associated with the prompt onset of euphoria exclusively following intranasal use. Mr. A was a 51-year-old polydrug abuser with antisocial personality disorder and a physical dependence on zolpidem. Over several years, he consumed 500 mg of the drug daily, usually divided into 30 mg doses, exclusively via the nasal route because unlike the oral administration of the same dose of the drug, intranasal administration induced euphoria. Euphoric effects manifested 3-5 minutes after taking the drug, and pronounced withdrawal symptoms (i.e., profu...
Source: Psychopharmacology Bulletin - April 11, 2024 Category: Psychiatry & Psychology Authors: Branimir Margeti ć Marina Alaber Source Type: research
Case Report on High Dose Lithium Treatment for Post-COVID Depression, Recurrent Fevers, and Skin Lesions
Psychopharmacol Bull. 2024 Apr 4;54(2):39-45.ABSTRACTThis is a case of a 35-year-old woman who presented with an 18-month history of post (long)-COVID depression and exhaustion along with recurrent fevers and treatment-resistant skin boils, all of which abated with lithium treatment at a serum level of 1.14 mmol/L, and all of which worsened when the lithium serum level was lowered to 0.8. This paper illustrates Lithium's effectiveness in the treatment of post (long)-COVID syndrome, though a higher serum concentration may be required.PMID:38601833 | PMC:PMC11003256 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - April 11, 2024 Category: Psychiatry & Psychology Authors: Lila Elizabeth Massoumi Alan Rosenbaum Source Type: research
Efficacy of Rivastigmine Augmentation on Positive and Negative Symptoms, General Psychopathology, and Quality of Life in Patients with Chronic Schizophrenia: A Randomized Controlled Trial
Psychopharmacol Bull. 2024 Apr 4;54(2):15-27.ABSTRACTThe study aimed to assess Rivastigmine augmentation on positive and negative symptoms (PNSs), general psychopathology, and quality of life in patients with chronic Schizophrenia. A double-blind, parallel-design, randomized, placebo-controlled trial of 60 schizophrenia patients was conducted. Intervention group received rivastigmine 3 mg/day + Treatment as Usual (TAU) and the control group: TAU + placebo. Negative and positive symptoms, general psychopathology; and quality of life were measured using Positive and Negative Symptom Scale (PANSS) and Manchester Short Assessm...
Source: Psychopharmacology Bulletin - April 11, 2024 Category: Psychiatry & Psychology Authors: Sepideh Herizchi Ali Reza Shafiee-Kandjani Mostafa Farahbakhsh Zahra Jahangiri Shahriyar Ghanbarzadeh Javid Hosein Azizi Source Type: research
Clozapine Prescripers-Dogmatic or Pragmatic?
Psychopharmacol Bull. 2024 Apr 4;54(2):46-50.ABSTRACTClozapine, amongst antipsychotics, has a unique composite mode of action that might translate into an expanded therapeutic potential on clinical grounds. Sorely, clozapine remains underutilized.PMID:38601835 | PMC:PMC11003257 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - April 11, 2024 Category: Psychiatry & Psychology Authors: Ahmed Naguy Hessa Alhazeem Source Type: research
